 Cory Christiansen
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Limbs | 33 | 2025 | 211 | 8.870 |
Why?
| | Walking | 37 | 2025 | 544 | 6.580 |
Why?
| | Gait | 26 | 2025 | 318 | 5.960 |
Why?
| | Amputees | 20 | 2025 | 98 | 5.670 |
Why?
| | Arthroplasty, Replacement, Knee | 18 | 2025 | 372 | 5.240 |
Why?
| | Exercise | 19 | 2025 | 2113 | 3.930 |
Why?
| | Osteoarthritis, Knee | 16 | 2025 | 270 | 3.710 |
Why?
| | Exercise Therapy | 15 | 2025 | 453 | 3.630 |
Why?
| | Veterans | 17 | 2025 | 1519 | 3.150 |
Why?
| | Lower Extremity | 20 | 2025 | 437 | 3.090 |
Why?
| | Tibia | 10 | 2024 | 182 | 2.460 |
Why?
| | Walk Test | 8 | 2024 | 79 | 2.210 |
Why?
| | Resistance Training | 3 | 2025 | 169 | 2.190 |
Why?
| | Movement | 12 | 2025 | 289 | 2.140 |
Why?
| | Muscle Strength | 12 | 2025 | 328 | 1.990 |
Why?
| | Multiple Sclerosis | 6 | 2024 | 468 | 1.960 |
Why?
| | Parkinson Disease | 10 | 2025 | 571 | 1.930 |
Why?
| | Middle Aged | 88 | 2025 | 34658 | 1.850 |
Why?
| | Aged | 73 | 2025 | 24836 | 1.840 |
Why?
| | Range of Motion, Articular | 14 | 2025 | 413 | 1.790 |
Why?
| | Biomechanical Phenomena | 30 | 2025 | 843 | 1.780 |
Why?
| | Femur | 8 | 2025 | 261 | 1.720 |
Why?
| | Activities of Daily Living | 7 | 2024 | 429 | 1.710 |
Why?
| | Knee Joint | 13 | 2025 | 411 | 1.600 |
Why?
| | Recovery of Function | 13 | 2025 | 684 | 1.600 |
Why?
| | Accidental Falls | 5 | 2025 | 215 | 1.580 |
Why?
| | Torso | 6 | 2021 | 35 | 1.470 |
Why?
| | Osteoarthritis, Hip | 3 | 2024 | 48 | 1.470 |
Why?
| | Telerehabilitation | 4 | 2025 | 39 | 1.440 |
Why?
| | Accelerometry | 7 | 2025 | 108 | 1.400 |
Why?
| | Self-Management | 3 | 2024 | 200 | 1.300 |
Why?
| | Weight-Bearing | 9 | 2025 | 174 | 1.290 |
Why?
| | Disability Evaluation | 7 | 2023 | 304 | 1.280 |
Why?
| | Male | 82 | 2025 | 70140 | 1.250 |
Why?
| | Resilience, Psychological | 2 | 2021 | 132 | 1.130 |
Why?
| | Female | 81 | 2025 | 75814 | 1.120 |
Why?
| | Humans | 116 | 2025 | 141284 | 1.120 |
Why?
| | Telemedicine | 4 | 2025 | 893 | 1.110 |
Why?
| | Self Efficacy | 4 | 2025 | 404 | 1.090 |
Why?
| | Prosthesis Design | 6 | 2025 | 342 | 1.080 |
Why?
| | Health Behavior | 5 | 2024 | 784 | 1.070 |
Why?
| | Hip Joint | 7 | 2025 | 176 | 1.060 |
Why?
| | Muscle, Skeletal | 8 | 2025 | 1747 | 0.960 |
Why?
| | Task Performance and Analysis | 3 | 2024 | 196 | 0.950 |
Why?
| | Osseointegration | 10 | 2025 | 71 | 0.950 |
Why?
| | Cross-Sectional Studies | 19 | 2025 | 5653 | 0.940 |
Why?
| | Arthroplasty, Replacement, Hip | 4 | 2025 | 187 | 0.880 |
Why?
| | Joints | 1 | 2025 | 105 | 0.840 |
Why?
| | Single-Blind Method | 6 | 2024 | 289 | 0.830 |
Why?
| | Biofeedback, Psychology | 3 | 2025 | 36 | 0.830 |
Why?
| | Mobility Limitation | 3 | 2018 | 63 | 0.800 |
Why?
| | Aged, 80 and over | 22 | 2025 | 7948 | 0.790 |
Why?
| | Exercise Test | 9 | 2024 | 620 | 0.710 |
Why?
| | Pelvis | 2 | 2020 | 117 | 0.700 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2021 | 7 | 0.690 |
Why?
| | Physical Therapy Modalities | 5 | 2020 | 320 | 0.690 |
Why?
| | Feasibility Studies | 7 | 2025 | 1037 | 0.680 |
Why?
| | Tobacco Smoking | 1 | 2021 | 25 | 0.680 |
Why?
| | Mechanical Phenomena | 1 | 2020 | 86 | 0.620 |
Why?
| | Adult | 33 | 2025 | 39319 | 0.600 |
Why?
| | Prosthesis Implantation | 7 | 2024 | 156 | 0.590 |
Why?
| | Bone Density | 4 | 2018 | 496 | 0.590 |
Why?
| | Teriparatide | 1 | 2018 | 9 | 0.590 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2018 | 25 | 0.590 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2024 | 1610 | 0.560 |
Why?
| | Hip | 3 | 2025 | 57 | 0.540 |
Why?
| | Postural Balance | 5 | 2024 | 238 | 0.540 |
Why?
| | Patient Reported Outcome Measures | 4 | 2025 | 451 | 0.530 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 416 | 0.490 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 561 | 0.480 |
Why?
| | Walking Speed | 1 | 2016 | 51 | 0.460 |
Why?
| | Behavior Therapy | 1 | 2018 | 282 | 0.450 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 680 | 0.440 |
Why?
| | Peripheral Vascular Diseases | 1 | 2015 | 104 | 0.430 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 32 | 0.430 |
Why?
| | Arthralgia | 1 | 2015 | 57 | 0.430 |
Why?
| | Quadriceps Muscle | 4 | 2024 | 118 | 0.430 |
Why?
| | Postoperative Period | 4 | 2025 | 359 | 0.420 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 1408 | 0.420 |
Why?
| | Diabetic Angiopathies | 3 | 2019 | 250 | 0.380 |
Why?
| | Patient Satisfaction | 5 | 2025 | 695 | 0.360 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 5948 | 0.320 |
Why?
| | Oxygen Consumption | 2 | 2025 | 712 | 0.290 |
Why?
| | Muscle Stretching Exercises | 1 | 2008 | 19 | 0.280 |
Why?
| | Preoperative Period | 2 | 2025 | 143 | 0.280 |
Why?
| | Bone Density Conservation Agents | 3 | 2015 | 83 | 0.280 |
Why?
| | Ankle | 1 | 2008 | 61 | 0.270 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2018 | 2529 | 0.270 |
Why?
| | Quality of Life | 6 | 2025 | 3024 | 0.270 |
Why?
| | Dependent Ambulation | 2 | 2019 | 10 | 0.270 |
Why?
| | Disease Progression | 2 | 2015 | 2808 | 0.270 |
Why?
| | Case-Control Studies | 5 | 2021 | 3577 | 0.250 |
Why?
| | Phenotype | 1 | 2015 | 3172 | 0.240 |
Why?
| | Pilot Projects | 2 | 2024 | 1820 | 0.240 |
Why?
| | Social Support | 2 | 2020 | 629 | 0.230 |
Why?
| | Kinetics | 2 | 2020 | 1620 | 0.230 |
Why?
| | Calcitonin | 2 | 2015 | 29 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2025 | 16447 | 0.220 |
Why?
| | Patient Compliance | 3 | 2020 | 607 | 0.220 |
Why?
| | Loneliness | 1 | 2025 | 54 | 0.220 |
Why?
| | Synovitis | 2 | 2015 | 36 | 0.220 |
Why?
| | Multimorbidity | 1 | 2025 | 54 | 0.210 |
Why?
| | Pain Measurement | 3 | 2025 | 555 | 0.210 |
Why?
| | Treatment Outcome | 10 | 2025 | 11216 | 0.210 |
Why?
| | Equivalence Trials as Topic | 1 | 2024 | 33 | 0.210 |
Why?
| | Cohort Studies | 4 | 2021 | 5809 | 0.210 |
Why?
| | Pain | 2 | 2024 | 779 | 0.200 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3345 | 0.200 |
Why?
| | Leg | 2 | 2016 | 239 | 0.200 |
Why?
| | Confidence Intervals | 2 | 2018 | 328 | 0.200 |
Why?
| | Functional Laterality | 1 | 2024 | 242 | 0.200 |
Why?
| | Patient Participation | 2 | 2024 | 427 | 0.200 |
Why?
| | Exercise Tolerance | 1 | 2025 | 281 | 0.190 |
Why?
| | Low Back Pain | 1 | 2024 | 109 | 0.190 |
Why?
| | Cumulative Trauma Disorders | 1 | 2022 | 31 | 0.180 |
Why?
| | Regional Blood Flow | 1 | 2024 | 497 | 0.180 |
Why?
| | Qualitative Research | 3 | 2025 | 1519 | 0.180 |
Why?
| | Peripheral Arterial Disease | 2 | 2019 | 491 | 0.180 |
Why?
| | Prospective Studies | 5 | 2025 | 7805 | 0.180 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.180 |
Why?
| | CpG Islands | 1 | 2021 | 164 | 0.160 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 172 | 0.160 |
Why?
| | Smokers | 1 | 2021 | 146 | 0.160 |
Why?
| | United Kingdom | 1 | 2021 | 321 | 0.160 |
Why?
| | Decision Support Techniques | 1 | 2024 | 433 | 0.160 |
Why?
| | Time Factors | 4 | 2025 | 6951 | 0.160 |
Why?
| | Cross-Over Studies | 2 | 2025 | 578 | 0.150 |
Why?
| | Double-Blind Method | 5 | 2019 | 1992 | 0.150 |
Why?
| | United States | 4 | 2025 | 15298 | 0.150 |
Why?
| | Mammography | 1 | 2000 | 157 | 0.150 |
Why?
| | Proof of Concept Study | 1 | 2019 | 84 | 0.150 |
Why?
| | Risk Factors | 6 | 2025 | 10490 | 0.150 |
Why?
| | Sulfonylurea Compounds | 1 | 2018 | 50 | 0.140 |
Why?
| | Patient Discharge | 1 | 2025 | 915 | 0.140 |
Why?
| | Placebos | 1 | 2018 | 195 | 0.140 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 59 | 0.140 |
Why?
| | Heart Rate | 3 | 2025 | 835 | 0.140 |
Why?
| | Thiazolidinediones | 1 | 2018 | 134 | 0.140 |
Why?
| | High-Intensity Interval Training | 1 | 2018 | 31 | 0.140 |
Why?
| | Self-Assessment | 1 | 2018 | 75 | 0.130 |
Why?
| | Diet, Reducing | 1 | 1998 | 90 | 0.130 |
Why?
| | User-Computer Interface | 1 | 1998 | 163 | 0.130 |
Why?
| | Radiography | 3 | 2015 | 845 | 0.130 |
Why?
| | Feedback | 1 | 2017 | 177 | 0.130 |
Why?
| | Psychometrics | 1 | 2021 | 736 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2021 | 579 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 661 | 0.120 |
Why?
| | Postmenopause | 1 | 1998 | 369 | 0.120 |
Why?
| | Ulna | 1 | 1996 | 36 | 0.120 |
Why?
| | Bone and Bones | 1 | 2018 | 312 | 0.120 |
Why?
| | DNA Methylation | 1 | 2021 | 643 | 0.120 |
Why?
| | Amputation, Traumatic | 1 | 2016 | 21 | 0.120 |
Why?
| | Radius | 1 | 1996 | 52 | 0.120 |
Why?
| | Spine | 1 | 2017 | 179 | 0.120 |
Why?
| | Posture | 1 | 2017 | 193 | 0.120 |
Why?
| | Knee Prosthesis | 1 | 2015 | 26 | 0.120 |
Why?
| | Acceleration | 1 | 2015 | 36 | 0.110 |
Why?
| | Perception | 1 | 2018 | 375 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 330 | 0.110 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2012 | 42 | 0.110 |
Why?
| | Synovial Membrane | 1 | 2015 | 119 | 0.110 |
Why?
| | Research Design | 2 | 2020 | 1105 | 0.110 |
Why?
| | Cognition Disorders | 1 | 1998 | 520 | 0.110 |
Why?
| | Psychomotor Performance | 1 | 2016 | 328 | 0.100 |
Why?
| | Computer Simulation | 1 | 1998 | 1009 | 0.100 |
Why?
| | Lumbar Vertebrae | 1 | 1996 | 252 | 0.100 |
Why?
| | Cartilage, Articular | 2 | 2015 | 333 | 0.100 |
Why?
| | Face | 1 | 2015 | 174 | 0.100 |
Why?
| | Motivation | 1 | 2018 | 600 | 0.100 |
Why?
| | Torque | 1 | 2013 | 80 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2018 | 592 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2009 | 298 | 0.100 |
Why?
| | Patient Safety | 1 | 2017 | 335 | 0.100 |
Why?
| | Brain Injuries | 1 | 1998 | 503 | 0.100 |
Why?
| | Osteoarthritis | 1 | 2015 | 202 | 0.100 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 306 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2904 | 0.090 |
Why?
| | Thigh | 1 | 2012 | 49 | 0.090 |
Why?
| | Peptide Fragments | 2 | 2015 | 696 | 0.090 |
Why?
| | Parathyroid Hormone | 1 | 2012 | 111 | 0.090 |
Why?
| | Mass Screening | 1 | 2000 | 1309 | 0.090 |
Why?
| | Proteins | 1 | 1998 | 1007 | 0.090 |
Why?
| | Precision Medicine | 1 | 2015 | 435 | 0.090 |
Why?
| | Reference Values | 2 | 2013 | 803 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1671 | 0.080 |
Why?
| | Heart Failure | 1 | 2024 | 2096 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 1013 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1395 | 0.080 |
Why?
| | Prognosis | 2 | 2015 | 4080 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1380 | 0.070 |
Why?
| | Metatarsophalangeal Joint | 1 | 2008 | 11 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2000 | 2246 | 0.070 |
Why?
| | Models, Biological | 1 | 2015 | 1810 | 0.070 |
Why?
| | Etidronic Acid | 1 | 2007 | 5 | 0.070 |
Why?
| | Ambulatory Care Facilities | 1 | 2010 | 245 | 0.070 |
Why?
| | Linear Models | 3 | 2013 | 855 | 0.070 |
Why?
| | Incidence | 1 | 2015 | 2809 | 0.070 |
Why?
| | Collagen Type I | 3 | 2015 | 140 | 0.070 |
Why?
| | Hepatitis C | 1 | 2010 | 250 | 0.070 |
Why?
| | Fractures, Spontaneous | 1 | 2007 | 16 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2022 | 416 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2091 | 0.060 |
Why?
| | Body Mass Index | 1 | 2015 | 2390 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3734 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1312 | 0.060 |
Why?
| | Anger | 1 | 2025 | 62 | 0.050 |
Why?
| | Obesity | 1 | 1998 | 3007 | 0.050 |
Why?
| | Aging | 1 | 2015 | 1919 | 0.050 |
Why?
| | Collagen Type II | 2 | 2015 | 55 | 0.050 |
Why?
| | Osteoporosis | 1 | 2007 | 242 | 0.050 |
Why?
| | Canada | 1 | 2025 | 420 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 314 | 0.050 |
Why?
| | Foot | 1 | 2024 | 99 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 538 | 0.050 |
Why?
| | Antiparkinson Agents | 1 | 2022 | 40 | 0.050 |
Why?
| | Knee | 1 | 2023 | 69 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 113 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 61 | 0.050 |
Why?
| | Biomarkers | 4 | 2015 | 4180 | 0.040 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 142 | 0.040 |
Why?
| | Goals | 1 | 2023 | 177 | 0.040 |
Why?
| | Administration, Oral | 2 | 2015 | 825 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2025 | 839 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 367 | 0.040 |
Why?
| | Sampling Studies | 1 | 2000 | 102 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2000 | 122 | 0.040 |
Why?
| | Physical Examination | 1 | 2022 | 243 | 0.040 |
Why?
| | Community-Based Participatory Research | 1 | 2021 | 162 | 0.040 |
Why?
| | Health Maintenance Organizations | 1 | 2000 | 105 | 0.040 |
Why?
| | Needs Assessment | 1 | 2022 | 388 | 0.040 |
Why?
| | Focus Groups | 1 | 2022 | 565 | 0.040 |
Why?
| | Clinical Clerkship | 1 | 2000 | 106 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 124 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1998 | 168 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1998 | 53 | 0.030 |
Why?
| | Risk | 1 | 2000 | 903 | 0.030 |
Why?
| | Odds Ratio | 1 | 2000 | 1057 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 89 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2047 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 185 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 337 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 771 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 859 | 0.030 |
Why?
| | Models, Statistical | 1 | 2000 | 669 | 0.030 |
Why?
| | Leptin | 1 | 1998 | 238 | 0.030 |
Why?
| | Peptides | 2 | 2015 | 971 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1043 | 0.030 |
Why?
| | Facial Muscles | 1 | 2015 | 7 | 0.030 |
Why?
| | Cheek | 1 | 2015 | 17 | 0.030 |
Why?
| | Subcutaneous Tissue | 1 | 2015 | 25 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2000 | 579 | 0.030 |
Why?
| | Students, Medical | 1 | 2000 | 370 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1268 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2000 | 2069 | 0.030 |
Why?
| | Eyelids | 1 | 2015 | 42 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 1996 | 266 | 0.030 |
Why?
| | Collagen Type III | 1 | 2013 | 18 | 0.030 |
Why?
| | Body Composition | 1 | 1998 | 704 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 582 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2013 | 95 | 0.020 |
Why?
| | Isometric Contraction | 1 | 2013 | 184 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2015 | 645 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 768 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 849 | 0.020 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 12 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 432 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2929 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 526 | 0.020 |
Why?
| | Urban Health | 1 | 2010 | 95 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1362 | 0.020 |
Why?
| | Hepacivirus | 1 | 2010 | 239 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1998 | 5222 | 0.020 |
Why?
| | Bone Resorption | 1 | 2007 | 84 | 0.020 |
Why?
| | Area Under Curve | 1 | 2007 | 324 | 0.020 |
Why?
| | Hip Fractures | 1 | 2007 | 85 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2840 | 0.010 |
Why?
| | Adolescent | 2 | 2015 | 22116 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2795 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9820 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11511 | 0.010 |
Why?
| | Massachusetts | 1 | 2000 | 176 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3295 | 0.010 |
Why?
| | Teaching | 1 | 2000 | 233 | 0.010 |
Why?
| | Risk Assessment | 1 | 2007 | 3522 | 0.010 |
Why?
| | Child | 1 | 2015 | 22390 | 0.010 |
Why?
| | Primary Health Care | 1 | 2000 | 1757 | 0.000 |
Why?
|
|
Christiansen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|